The present study aimed at evaluating the effect of opicapone, a third generation nitrocatechol catechol-O-methyltransferase (COMT) inhibitor, on the systemic and central bioavailability of 3,4-dihydroxy-l-phenylalanine (levodopa) and related metabolites in the cynomolgus monkey. Four monkeys, implanted with guiding cannulas for microdialysis probes, in the substantia nigra, dorsal striatum and prefrontal cortex, were randomized in two groups that received, in a crossover design, vehicle or 100 mg/kg opicapone for 14 days. Twenty-three hours after last administration of vehicle or opicapone, animals were challenged with levodopa/benserazide (12/3 mg/kg). Extracellular dialysate and blood samples were collected over 360 min (at 30 min intervals) for the assays of catecholamine and COMT activity. Opicapone increased levodopa systemic exposure by 2-fold not changing Cmax values and reduced both 3-O-methyldopa (3-OMD) exposure and Cmax values by 5-fold. These changes were accompanied by ∼76-84% reduction in erythrocyte COMT activity. In dorsal striatum and substantia nigra, opicapone increased levodopa exposure by 1.7- and 1.4-fold, respectively, reducing 3-OMD exposure by 5- and 7-fold respectively. DOPAC exposure was increased by 4-fold in the substantia nigra. In the prefrontal cortex, opicapone increased levodopa exposure and reduced 3-OMD levels by 2.3- and 2.4-fold, respectively. Opicapone behaved as long-acting COMT inhibitor that markedly increased systemic and central levodopa bioavailability. Opicapone is a strong candidate to fill the unmet need for COMT inhibitors that lead to more sustained levodopa levels in Parkinson's disease patients.
The present study aimed at evaluating the effect of opicapone , a third generation nitrocatechol catechol - O - methyltransferase ( COMT ) inhibitor , on the systemic and central bioavailability of 3,4-dihydroxy - l - phenylalanine ( levodopa ) and related metabolites in the cynomolgus monkey . Four monkeys , implanted with guiding cannulas for microdialysis probes , in the substantia nigra , dorsal striatum and prefrontal cortex , were randomized in two groups that received , in a crossover design , vehicle or 100 mg / kg opicapone for 14 days . Twenty - three hours after last administration of vehicle or opicapone , animals were challenged with levodopa / benserazide ( 12/3 mg / kg ) . Extracellular dialysate and blood samples were collected over 360 min ( at 30 min intervals ) for the assays of catecholamine and COMT activity . Opicapone increased levodopa systemic exposure by 2-fold not changing Cmax values and reduced both 3-O - methyldopa ( 3-OMD ) exposure and Cmax values by 5-fold . These changes were accompanied by ∼76 - 84 % reduction in erythrocyte COMT activity . In dorsal striatum and substantia nigra , opicapone increased levodopa exposure by 1.7- and 1.4-fold , respectively , reducing 3-OMD exposure by 5- and 7-fold respectively . DOPAC exposure was increased by 4-fold in the substantia nigra . In the prefrontal cortex , opicapone increased levodopa exposure and reduced 3-OMD levels by 2.3- and 2.4-fold , respectively . Opicapone behaved as long - acting COMT inhibitor that markedly increased systemic and central levodopa bioavailability . Opicapone is a strong candidate to fill the unmet need for COMT inhibitors that lead to more sustained levodopa levels in Parkinson 's disease patients .
What enzyme is inhibied by Opicapone?
What enzyme is inhibied by Opicapone ?
catechol-O-methyltransferase
catechol-O-methyltransferase